Production (Stage)
MediXall Group, Inc.
MDXL
$0.0039
$0.000411.43%
OTC PK
| 03/31/2024 | 12/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 24.97% | 44.27% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 24.97% | 44.27% | |||
| Cost of Revenue | -45.54% | 79.16% | |||
| Gross Profit | 67.08% | -93.56% | |||
| SG&A Expenses | -69.50% | -5.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -60.48% | 14.63% | |||
| Operating Income | 68.74% | -12.40% | |||
| Income Before Tax | 66.55% | -60.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 66.55% | -60.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 66.55% | -60.17% | |||
| EBIT | 68.74% | -12.40% | |||
| EBITDA | 67.96% | -9.44% | |||
| EPS Basic | 64.10% | -53.95% | |||
| Normalized Basic EPS | 67.14% | -62.79% | |||
| EPS Diluted | 64.10% | -17.00% | |||
| Normalized Diluted EPS | 67.14% | -62.79% | |||
| Average Basic Shares Outstanding | 2.70% | 0.03% | |||
| Average Diluted Shares Outstanding | 2.70% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||